Physician profile
Nicole M Watson
NPI 1154748556
$730.80
in general payments reported to CMS, 2019-2025
17 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $594 · 2023: $23.02 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $136.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $113.40 | 2025 | |
| Glaxosmithkline, LLC. | $97.68 | 2021 | |
| Amarin Pharma, INC. | $87.09 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.87 | 2021 | |
| Abbvie INC. | $48.32 | 2021 | |
| Lilly USA, LLC | $46.20 | 2021 | |
| Pfizer INC. | $41.85 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $37.97 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.41 | 2021 | |
| Esperion Therapeutics, INC. | $31.11 | 2021 | |
| Novo Nordisk INC | $28.90 | 2021 | |
| International Rehabilitative Sciences, INC | $23.02 | 2023 | Rs 4i Plus Sequential Stimulator |
| Vanda Pharmaceuticals INC. | $20.93 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.64 | 2021 | |
| Merck Sharp & Dohme LLC | $18.24 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $14.61 | 2021 | |
| Nestle Healthcare Nutrition INC. | $14.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.